Clinical-stage biotechnology company pioneering the field of cell therapies
Allogene Therapeutics is a clinical-stage biotechnology company, focusing on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
Developing off-the-shelf CAR T cell therapy candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients. These off-the-shelf CAR T therapies, enhanced by gene editing, could be the next most important breakthrough in the field.
Allogene is on a mission to create and lead the next revolution in cancer treatment by delivering to patients the first AlloCAR T™ therapies for blood cancers and solid tumors.
Visit website: https://www.allogene.com/
Allogene Therapeutics News
FDA puts clinical hold on Allogenic CAR T therapy due to safety concerns
FierceBiotech - 08-Oct-2021
Chromosome abnormality reported in a clinical trial raises doubts on patient safetyRead more...